ASPC
A SPAC III Acquisition Corp.10.50
-0.05-0.52%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
24.53MP/E (TTM)
-Basic EPS (TTM)
-0.34Dividend Yield
0%Recent Filings
8-K
SPAC extends combination deadline
A SPAC III Acquisition Corp. extended its deadline to complete an initial business combination by 12 months to November 12, 2026, after shareholders approved the charter amendment at an October 27, 2025 extraordinary general meeting. With 4,178,733 votes in favor against 2,934,951 opposed, 5,717,419 shares were redeemed, leaving the SPAC with fewer public shares. The sponsor secured support from a third party by promising 100,000 Class B shares post-combination. This buys time, yet redemptions shrink the trust.
10-Q
Q2 FY2025 results
A SPAC III Acquisition Corp. posted a net income of $379,939 for Q2 FY2025 ended June 30, 2025, up sharply from a $8,000 loss a year earlier, thanks to $646,975 in interest income from its $61.6M trust account, while general and administrative expenses climbed to $267,036 from $8,000 on heightened public company costs. Year-to-date through June 30, net income hit $793,141 versus a $8,000 loss last year, with interest income at $1.3M offsetting $500,914 in expenses; redeemable shares earned $0.22 per share on 6M shares, but non-redeemable shares absorbed a $0.24 loss per share on 2.055M shares due to accretion charges (derived). Cash stood at $1.1M outside the trust, with no debt after repaying a related-party note, supporting merger pursuits. On May 23, 2025, the company signed a merger deal with Bioserica International for $217.9M in stock (20M Class B and 1.786M Class A shares at $10 each, assuming $12.5M third-party investment), involving a reincorporation merger and Bioserica as a wholly owned subsidiary, backed by a shareholder voting agreement. Geopolitical tensions could disrupt the deal.
8-K
SPAC inks $200M Bioserica merger
A SPAC III Acquisition Corp. signed a merger agreement on May 23, 2025, to acquire Bioserica International Limited through a reincorporation merger followed by an acquisition merger, valuing Bioserica at $200 million in stock consideration, including up to 1,786,000 Class A shares. This deal, backed by a voting agreement from a key Bioserica shareholder, aims to bring the target public via Nasdaq while navigating CSRC and CAC approvals. Closing hinges on shareholder votes and no material adverse effects. Deal could falter if redemptions drain the trust.
10-Q
Q1 FY2025 results
A SPAC III Acquisition Corp. posted a net income of $413,202 for Q1 FY2025 ended March 31, 2025, driven by $647,080 in interest income from its $60.0M trust account, offset by $233,878 in general and administrative expenses—up from zero activity a year earlier. Cash outside the trust dipped to $1.1M from $1.6M q/q, with working capital at $982K after repaying a related-party note; no debt or capex disclosed. Non-GAAP metrics not disclosed in the 10-Q. Letters of intent signed in December 2024 for a $300M all-stock deal with HD Group and in January 2025 for a $200M all-stock deal with Bioserica, both pending definitive agreements. No business combination yet. Sponsor indemnity covers trust shortfalls. Geopolitical tensions pose risks to deal timelines.
10-K
FY2024 results
A SPAC III Acquisition Corp. completed its IPO in November 2024, raising $60 million in gross proceeds from 6 million units at $10 each, with funds deposited into a trust account yielding $360,723 in interest income for the year ended December 31, 2024. The company reported a net loss of $226,383, driven by $587,106 in general and administrative expenses amid pre-combination activities, while maintaining $1.6 million in cash outside the trust for working capital. No Q4-specific metrics are disclosed, but the IPO's late-year timing marked a pivotal momentum shift from prior years' minimal operations and $2,650 net loss in 2023. Liquidity remains solid with no debt outstanding, though the sponsor may provide working capital loans if needed. No annual guidance is provided, but non-binding agreements for business combinations with HD Group ($300 million) and Bioserica ($200 million), both in stock, signal active pursuit within the 12-month deadline. Failure to complete a combination risks liquidation, returning ~$10 per share to public holders.
AACI
Armada Acquisition Corp. II
10.29-0.01
ALSAF
Alpha Star Acquisition Corporat
17.50+0.00
BSAA
BEST SPAC I Acquisition Corp.
10.10+0.00
GPAT
GP-Act III Acquisition Corp.
10.66+0.00
HSPT
Horizon Space Acquisition II Co
10.62+0.06
IPCX
Inflection Point Acquisition Co
10.11+0.00
NPAC
New Providence Acquisition Corp
10.28+0.03
SPEG
Silver Pegasus Acquisition Corp
10.07-0.01
SPKL
Spark I Acquisition Corp.
11.23+0.08
SVII
Spring Valley Acquisition Corp.
12.70+0.00